PNEUMOCOCAL DETECTION PROCEDURE
A two-step immunological method for detecting pneumococcal antigens in respiratory secretions, including a diluted sample analysis, effectively distinguishes between asymptomatic carriage and invasive infections, enhancing diagnostic precision and reducing unnecessary treatments.
Patent Information
- Application Number
- FR2019005115
- Authority / Receiving Office
- FR · FR
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2019-05-16
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2039-05-16
AI Technical Summary
Current diagnostic methods for pneumococcal infections, such as those caused by Streptococcus pneumoniae, struggle to differentiate between asymptomatic carriage and invasive infections, particularly in children, due to low sensitivity and specificity, and often require invasive sampling or lengthy culture techniques.
A semi-quantitative diagnostic method involving two steps: an initial detection of pneumococcal antigens in respiratory tract secretions followed by a diluted sample analysis using immunological tests, allowing for precise differentiation between asymptomatic carriage and invasive infections.
The method provides rapid, reliable differentiation between asymptomatic carriage and invasive infections, reducing unnecessary antibiotic treatments and hospitalizations by accurately quantifying bacterial loads, with high sensitivity and specificity.
Smart Images

Figure 00000029_0000 
Figure 00000029_0001 
Figure 00000030_0000
Abstract
Description
Title of the invention: METHOD FOR DETECTING PNEUMOCOCS technical field
[0001] Pneumococcal infections are caused by a bacterium called Streptococcus pneumoniae.
[0002] Streptococcus pneumoniae, or pneumococcus, is a Gram-positive, catalase-negative bacterium that appears as a single bacterium, in diplococci, or in short chains under direct microscopic examination. The distinctive feature of pneumococcus is its capsule, one of its main virulence factors. This capsule is primarily composed of polysaccharides (designated CWPS for Cell Wall Polysaccharide) containing carbohydrate subunits that are targets of the immune response due to their antigenic properties.
[0003] Pneumococcus is a commensal of the airways in the human species, that is to say that it can be present at the level of the mouth, nose and pharynx without causing pathologies: 5 to 25% of the population is an asymptomatic carrier of the bacterium.
[0004] However, pneumococci can cause infections in many locations in the body: the middle ear (otitis) in children, the sinuses (sinusitis) in adults, the membranes of the brain (meningitis), the blood (bacteremia) and the respiratory tract (rhinopharyngitis, bronchitis, pneumonia).
[0005] Pneumococci are transmitted between people, by direct and close contact with the infected or carrier person, in particular during kissing, coughing, sneezing or by hand carriage.
[0006] Some pneumococcal infections can be serious, with septicemic dissemination of the bacteria, which requires urgent and sometimes heavy treatments (intravenous antibiotic therapy, hospitalization, or even resuscitation), with a non-negligible mortality rate in frail or elderly subjects.
[0007] Pneumococcal infections are a major cause of morbidity and mortality worldwide. More than 800,000 children under the age of 5 die each year from pneumococcal infections worldwide, according to the World Health Organization (WHO). In France, pneumococci are the leading cause of community-acquired pneumonia and bacterial meningitis in adults. Pneumococcal infections frequently complicate viral infections, particularly influenza, especially in vulnerable individuals. In young children, they are a common cause of otitis media and pneumonia.
[0008] In children in particular, pneumococcus is frequently present as an asymptomatic carrier but can also cause invasive infections of varying severity, some with a very rapid progression that can be life-threatening. Therefore, it is essential to distinguish early on between asymptomatic carriage and an early or progressive invasive infection. Previous technique
[0009] Clinical signs, symptoms and physical examinations alone cannot distinguish S. pneumoniae pneumonia from pneumonias due to other pathogens (other pyogenic bacteria, so-called atypical bacteria with intracellular multiplication, viruses ...).
[0010] The first-line biological diagnosis of S. pneumoniae pneumonia is based on: - cytobacteriological examination of sputum (ECBC), of limited interest due to the associated commensal flora, generally followed by a culture on a suitable medium (such as blood agar) which allows to distinguish and isolate the different bacterial colonies; - bronchoalveolar lavage (BAL) or pleural fluid aspiration, which are very invasive examinations but which provide a definitive diagnosis; indeed in this type of sample, the presence of any germ indicates an invasive infection; - Pneumococcal antigenuria: this is a simple and rapid test which detects in the urine a specific antigen common to all pathogenic serotypes of pneumococci; the antigen found in the urine comes from the degradation of the bacteria by the body's defense systems.
[0011] However, in urine, this antigen persists for several weeks and does not disappear following appropriate antibiotic therapy, which limits its diagnostic value in relation to the ongoing infectious episode. Furthermore, this diagnostic value varies considerably across studies, with good specificity, ranging from 92% to 99% (false positives have been described, particularly in patients with asthma or chronic obstructive pulmonary disease), and sensitivity that varies according to clinical severity (between 66% and 82%).
[0012] Kits for detecting pneumococcal antigens in respiratory tract secretions have been developed and compared to kits for detecting them in urine.
[0013] This is the case for the ODK0501 kit, which includes polyclonal antibodies directed against the C polysaccharide of S. pneumoniae. This test has been found to be more useful in clinical practice than urinary antigen detection kits (Ehara et al., 2008), (Izumikawa et al., 2009).
[0014] Another kit called RAPIRUN was tested in comparison with the BinaxNOW® kit used on urine samples: the RAPIRUN test on sputum showed better sensitivity than the urine test (Ikegame et al., 2016).
[0015] However, in children under 12 years of age, the use of these antigen tests on urine or sputum does not appear to be relevant for the diagnosis of S. pneumoniae infection due to the very frequent asymptomatic pneumococcal carriage in this age group. This is even more true in children under 5 years of age, for whom the prevalence of asymptomatic carriage is estimated to be between 57 and 65%.
[0016] To date, semi-quantitative culture on fresh blood agar and cooked blood agar at 48 hours is considered the "gold standard" for the diagnosis of S. pneumoniae pneumonia, regardless of the patient's age. Thus, in cases of suspected pneumonia in children, the standard procedure in the medical biology laboratory is as follows: a) perform bacterial culture on fresh blood agar and cooked blood agar, b) possibly, depending on the clinical symptoms and the epidemiological context, perform gene amplification testing for DNA of germs responsible for atypical pneumonias such as Mycoplasma pneumoniae or Chlamydia pneumoniae, c) perform quantitative gene amplification of S. pneumoniae, in particular by the Polymerase Chain Reaction (PCR) technique. The most commonly used targets of PCR tests are the gene encoding the main autolysin (lytA), the gene encoding pneumolysin (ply) and the capsular gene (cpsA).
[0017] The disadvantages of these detection methods are as follows:
[0018] In the case of culture on agar medium, colony detection is often made difficult by the polymicrobial context of the sample. Indeed, S. pneumoniae is a fragile organism, delicate to culture; the colonies are often small, and it is common to miss them among other colonies of less demanding and more invasive bacteria during culture.
[0019] The main drawback of the genomic amplification method is that the result is positive both in cases of true infection and in cases of asymptomatic carriage. This technique, unless it is quantitative, is therefore unsuitable for the diagnosis of invasive infection.
[0020] However, to distinguish an invasive infection from asymptomatic carriage, it is essential to quantify or semi-quantify the bacterial population: indeed, according to the recommendations of the French Society of Microbiology (REMIC, 6th edition, 2018), a high bacterial load (> 107 CFU / ml) in sputum is predictive of a genuine pneumococcal infection.
[0021] Currently, apart from semi-quantitative bacterial culture, which is long and tedious, or quantitative gene amplification, which is still very unavailable in routine practice, there is no method which allows us to quantify the bacterial population of S. pneumoniae, and therefore to differentiate an asymptomatic carriage from an invasive infection. Summary of the invention
[0022] The present invention relates to an in vitro diagnostic method for pneumococcal (Streptococcus pneumoniae) infection comprising at least two steps for detecting a pneumococcal antigen: (i) on a sample of secretions from the respiratory tract of a patient, and (ii) on the same sample after dilution.
[0023] These biological samples from the respiratory tract (sputum, etc.) are easy to obtain without invasive (traumatic) intervention for the patient.
[0024] The diagnostic method according to the invention being semi-quantitative, it makes it possible to differentiate between asymptomatic carriage of S. pneumoniae, common in the rhinopharyngeal sphere of the child (bacterial load < 107 CFU / ml), and true infection (bacterial load > 107 CFU / ml) requiring antibiotic treatment.
[0025] The present invention also relates to a diagnostic kit for carrying out the in vitro process as described above, comprising: - an immunological test comprising at least one antibody that binds specifically to at least one pneumococcal antigen; and - a dilution solution. Brief description of the drawings
[0026] [Fig. 1] Algorithm for managing pneumonia according to the diagnostic method of the invention. The PneumoResp immunological test is used for a first detection step on a "PURE" sample, then for a second detection step on a "DILUTE" sample. The diagnostic conclusions and suggested additional analyses are presented.
[0027] [fig.2] Correlation between bacterial load expressed as number of PCR cycles and The quantification in culture, expressed in CFU / ml (corresponding to the unit CFU / ml), of S. pneumoniae depends on the amplified gene: ply or lytA. The term "Ct" corresponds to the number of cycles from which a signal is detected by quantitative PCR. The number of cycles required to detect the bacterium by PCR is thus correlated with the actual quantity of the bacterial population.
[0028] [fig.3] Box plots studying the correlation between the quantity of S. pneumoniae (CFU / ml) as determined by the number of PCR cycles for ply gene amplification (based on the results in Figure 2), and the results of Detection steps of the process according to the invention: - A purely negative RDT (Rapid Detection Test) represents samples for which a negative result was obtained during the first detection step; - Pure positive TDR represents samples for which a positive result was obtained during the first detection step; - Positive diluted TDR represents samples for which a positive result was obtained during the second detection step.
[0029] The large horizontal bars represent the median for each situation. The small lower and upper bars represent the 25% quartile and the 75% quartile, respectively.
[0030] [fig.4] Reading the positive / negative results of the “PneumoResp” test
[0031] Line C is the internal control line, which must be positive; line T is the sample test line. Circle S represents the well in which a few drops of sample and migration buffer were placed to perform the test. Description of embodiments
[0032] The present invention relates to an in vitro diagnostic method for pneumococcal infection (also known as Streptococcus pneumoniae or S. pneumoniae) comprising at least two steps for detecting a pneumococcal antigen: (i) on a sample of secretions from the respiratory tract of a patient, and (ii) on the same sample after dilution.
[0033] By "pneumococcal infection" is meant an invasive infection (as opposed to colonization), also called a "true infection", characterized by the presence of a significant quantity of bacteria of the species S. pneumoniae in a sample.
[0034] This application relates specifically to pneumococcal respiratory infections, characterized by the presence of a significant quantity of S. pneumoniae bacteria in a sample of respiratory secretions (nasopharyngeal secretions, sputum, tracheal secretions, etc.) of human origin. According to the recommendations of the French Society for Microbiology (REMIC, 6th edition, 2018), a high bacterial load (> 10⁷ CFU / ml) in a sputum-type respiratory sample is predictive of an invasive pneumococcal infection.
[0035] Invasive pneumococcal respiratory infection includes S. pneumoniae pneumonia, but also higher respiratory infections (bronchitis, rhinopharyngitis, or even acute sinusitis or otitis media)
[0036] The present invention also relates to an in vitro diagnostic method for pneumococcal infection comprising a step of detecting a pneumococcal antigen on a sample of secretions from the respiratory tract of a patient, said sample being diluted.
[0037] For the purposes of this invention, the term "diluted sample" or "diluted sample" refers to a sample of respiratory secretions from a patient to which a certain volume of a suitable solution has been added in order to assess the concentration of bacteria present in the sample. This procedure makes the results obtained from the immunological test more precise and reliable.
[0038] The dilution factor will be chosen by a person skilled in the art based on their general knowledge. The dilution factor must be adapted to the sensitivity threshold of the immunological test used and to the patient population being tested.
[0039] For example, the dilution factor is between 2 and 1000, or between 10 and 500, or between 20 and 200, or between 50 and 150, or between 10 and 100, the bounds of each interval being included in the interval.
[0040] According to a preferred embodiment, the dilution factor is 100.
[0041] The advantages of these diagnostic methods include the following: - These processes can be carried out within a period of 15 to 40 minutes; they are very simple to implement and require very few reagents and no special equipment; - Obtaining a sample of secretions from an individual's respiratory tract is easy, through a non-invasive procedure; - A negative result in the first detection step, on an undiluted sample, allows for the near-certain exclusion of a serious pneumococcal infection, thus avoiding: a) For the laboratory, a pointless search for this germ, b) for the patient and the microbial ecology, inappropriate antibiotic therapy (research can be focused on other bacterial or viral pathogens), c) for the community, unnecessary or prolonged hospitalization.
[0042] This type of diagnostic procedure is also commonly referred to as "Rapid Diagnostic Test (RDT)" or "Rapid Diagnostic Orientation Test (RDOT)".
[0043] Nature of the sample and prior fluidization
[0044] The expression "secretions from the respiratory tract of a patient" refers to all secretions from the upper and lower respiratory tracts of the human body, excluding saliva.
[0045] This includes in particular any sampling of the upper respiratory tract, rhinopharyngeal secretions, tracheobronchial secretions (expectorations), induced sputum, nasopharyngeal aspiration, bronchial aspiration as well as bronchoalveolar lavage (BAL).
[0046] According to a preferred embodiment, the sample of secretions from the respiratory tract of a patient is liquefied prior to the implementation of the diagnostic procedure.
[0047] This fluidization can be achieved by all means known to the person skilled in the art, such as mechanical treatment of the sample (ultrasonic treatment, agitation in the presence of microbeads, etc.) or chemical treatment with a fluidizing agent.
[0048] Several chemical products with the ability to thin a secretion are known to those skilled in the art. For example, the thinning agent could be di-thiothreitol or N-acetylcysteine diluted to 50%. In particular, the thinning agent could be chosen from among the following commercial products: Digest-EUR® (Eurobio), Sputasol (ThermoFisher), or Mucomyst® (EurekaSanté).
[0049] Conventionally, a volume of thinning agent is added to a volume of sputum sample (dilution by a factor of 2). However, it is understood that a person skilled in the art may adjust the volume of thinning agent used, depending on the nature and consistency of the sample. Patient population
[0050] Any individual likely to have a pneumococcal infection may be tested according to the in vitro diagnostic method of the invention.
[0051] In the present application, the terms "individual" and "patient" are used interchangeably, and both refer to the human being from whom the respiratory tract secretions used in the diagnostic process according to the invention originate.
[0052] As already presented, this diagnostic method is particularly suited to the subpopulation of children under 12 years of age, and preferably to children under 5 years of age.
[0053] Thus, according to one implementation of the process, the patient from whom the respiratory tract secretions are taken is under 12 years of age, or is under 5 years of age.
[0054] However, the diagnostic method according to the invention may also be applied to patients aged 12 years and over, in particular to adults, and especially to persons over 70 years of age.
[0055] Immunological test used for the detection steps
[0056] The in vitro diagnostic method is characterized in that the detection steps are carried out using the same immunological test comprising at least one antibody that binds specifically to at least one pneumococcal antigen.
[0057] Said immunological test is characterized by (i) the nature of the antibody or antibodies included in said test and (ii) the type of immunological test (reagents, visualization of results). These two characteristics are developed below. Antibody / antigen pair
[0058] The immunological test comprises an antibody that specifically recognizes at least one pneumococcal antigen.
[0059] The concept of "specific antibody / antigen binding" means, in the sense of the invention, that the antibody recognizes and captures an antigen of S. pneumoniae in a specific manner, that is to say without cross-reaction with antigens of other bacterial species.
[0060] Advantageously, the immunological test used will not exhibit any cross-reaction with any of the following bacterial species, potentially present in the respiratory flora: Alloscardovia omnicolens, Enterococcus avium, Enterococcus faecalis, Enterococcus faecium, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Staphylococcus aureus, Streptococcus agalactiae, Streptococcus anginosus, Streptococcus constellatus, Streptococcus gordonii, Streptococcus pyogenes, Streptococcus salivarius, Streptococcus sanguinis, Streptococcus parasanguinis, Streptococcus mitis and Streptococcus vestibularis.
[0061] The detected S. pneumoniae antigen may be of any molecular nature, and may in particular be a protein, a lipid or a sugar, allowing S. pneumoniae to be specifically identified in a sample containing other bacterial species.
[0062] Each detection step will allow the detection of at least one pneumococcal antigen, that is to say one or more specific pneumococcal antigen(s), and this with one and the same antibody, or with several antibodies.
[0063] According to an advantageous implementation, the immunological test used is compatible with the main chemical fluidizers used in hospital medical biology laboratories.
[0064] Indeed, most fluidizers cause oxidation of the thiol groups of molecules when added to a biological sample. Thus, the structure of certain antigens can be modified, particularly that of protein antigens, which is likely to impair the recognition of said modified antigen by an antibody.
[0065] Consequently, when the biological sample has been previously fluidized by the addition of a chemical fluidifier, it is advantageous that the antibody or antibodies be directed against an antigen not modified by the fluidifier, for example an antigen of a non-protein nature, in particular an antigen consisting of a lipid or a sugar.
[0066] According to a preferred embodiment, the antibody included in the immunological test makes it possible to specifically detect at least one capsular polysaccharide of S. pneumoniae.
[0067] According to a particular embodiment, the antibody or antibodies included in said immunological test is / are directed against one or more capsular polysaccharide(s) of S. pneumoniae.
[0068] Immunological test used for a step of detecting at least one antigen pneumococcus
[0069] For the purposes of this invention, "immunological test" means a test that allows the detection of at least one S. pneumoniae antigen by means of at least one antibody that specifically recognizes this antigen, said antibody being coupled to a detectable reagent, or to an enzyme that reacts to the addition of a detection reagent.
[0070] Said detection reagent may in particular be a colored, fluorescent, luminescent reagent, or any type of detection reagent that can be detected and / or quantified by techniques well known to those skilled in the art.
[0071] A person skilled in the art is familiar with many types of immunological tests for detecting specific antigens. The present diagnostic method can be performed with any type of immunological test capable of specifically identifying at least one S. pneumoniae antigen.
[0072] A commonly used immunological test is, for example, the so-called "ELIS A" test for Enzyme-linked immunosorbent assay, in which two types of antibodies are used, one being specific to the antigen to be detected, and the other reacting to antigen-antibody complexes and being coupled to an enzyme capable of generating the emission of a signal in the presence of a chromogenic or fluorogenic substrate.
[0073] Other classic immunological tests are called 'immunochromatographic' type. These tests combine antigen detection by antibody with migration of the antigen / antibody complex on a chromatographic membrane.
[0074] Some immunochromatographic tests are based on the use of antibodies coupled to nanoparticles, particularly gold nanoparticles. The migration of the antibodies, possibly bound to at least one antigen, takes place on a suitable membrane. The results are read rapidly, generally in 10 to 20 minutes. The immunoassay should be used according to the instructions given in the test package insert.
[0075] According to a preferred embodiment of the method according to the invention, the immunological test used to detect one or more S. pneumoniae antigen(s) is an immunochromatographic test.
[0076] According to a particular embodiment, the immunological test is an immunochromatographic test comprising at least one antibody that binds specifically to a capsular polysaccharide of S. pneumoniae.
[0077] According to another particular embodiment, the immunological test is an immunochromatographic test comprising at least one antibody that binds specifically to the C polysaccharide of S. pneumoniae.
[0078] Although most of the S. pneumoniae-specific immunochromatographic tests currently available on the market are indicated for detecting the pneumococci in urine or cerebrospinal fluid samples, these tests can also be used, within the framework of the process according to the invention, on samples taken from the respiratory tract of a patient.
[0079] Thus, the tests that can be used for implementing the diagnostic process according to the invention include, in particular, the following: - the PneumoSpeed test marketed by BIOSPEEDIA, - the BinaxNOW® test marketed by ALERE, - the Tru Strep Pneumo™ test marketed by MERIDIAN, - the Uni-Gold™ S. pneumoniae test marketed by TRINITY BIOTECH, - the Sofia S. pneumoniae FIA test marketed by QUIDEL, - the Pneumo test marketed by BIOSYNEX.
[0080] Other tests developed specifically for detection on samples of secretions from the respiratory tract may be used, such as the Rapirun® and ODK0501 kits.
[0081] Advantageously, the detection steps of the process according to the invention implement the S. pneumoniae capsular polysaccharide detection test "PneumoResp" developed by BIOSPEEDIA, the characteristics of which are presented in Example 4.
[0082] Method for semi-quantification of pneumococci present in the sample
[0083] According to a particular embodiment of the process according to the invention, steps (i) and (ii) are carried out successively, that is to say that the process comprises at least two steps of detection of a pneumococcal antigen: (i) on a sample of secretions from a patient's respiratory tract, then (ii) on the same sample after dilution according to an appropriate factor, for example by a dilution factor of 10 to 1000, preferably by a factor of 100.
[0084] The diagnostic method according to the invention is characterized in that at the end of each detection step, a "positive" or "negative" result is obtained by implementing the immunological test.
[0085] Advantageously, this result is a semi-quantitative result, because it allows us to evaluate the quantity of pneumococci present in the sample.
[0086] Indeed, a "negative" result obtained at the end of the first detection step (i) is representative of a quantity of pneumococci in the sample that is less than or equal to 10³ CFU / ml. This quantity was determined by comparing the results obtained on more than 200 samples subjected to several tests in parallel: a) a quantitative bacteriological culture, b) amplification of S. pneumoniae DNA by PCR, and c) the method according to the invention.
[0087] Such a negative result may be interpreted as being representative of the absence of an invasive pneumococcal infection and will allow us to conclude that the tested patient does not have an invasive pneumococcal infection.
[0088] Of the 65 patient samples tested according to the method of the invention, which showed a negative result following the first detection step on an undiluted sample, no S. pneumoniae pneumonia was clinically diagnosed.
[0089] In some cases, the sample has been pre-fluidified by adding a certain volume of a fluidizing agent. Because of this pre-dilution, it would not be correct to designate the method of the invention as "quantitative"; nevertheless, the designation "semi-quantitative" method applies here insofar as reliable information on the quantity of pneumococci present in the sample is obtained by implementing the detection test, which has been compared to the results obtained by conventional semi-quantification methods, as shown in the examples in the application.
[0090] In the experiments presented in the experimental part, after a dilution of one hundredth of the sample, the sensitivity of the test is close to the threshold of 107 CFU / ml (see figure 3), which corresponds to the value considered to be significant for recognizing the involvement of this bacterium in the etiology of a pulmonary parenchymal infection.
[0091] A person skilled in the art may perform as many dilutions of the sample and detection steps as they wish: for example, the process may include a detection step on a pure sample, a detection step on a sample diluted by a factor of 10, and then a detection step on a sample diluted by a factor of 100.
[0092] The sample will be diluted in a suitable solution.
[0093] The dilution factor will be chosen by a person skilled in the art based on their general knowledge. Preferably, the dilution factor will be adapted to the sensitivity threshold of the immunological test used and / or to the patient population tested.
[0094] For example, the dilution factor is between 2 and 1000, or between 10 and 500, or between 20 and 200, or between 50 and 150, or between 10 and 100, the bounds of each interval being included in the interval.
[0095] According to a preferred embodiment, the dilution factor is 100, i.e. a dilution of a factor of 102.
[0096] According to one implementation of the process, it further includes a step (iii) of comparing the results obtained in steps (i) and (ii).
[0097] Indeed, the results obtained in the detection steps (i) and (ii) can be either similar (positive then positive), or different (positive then negative).
[0098] Depending on the concordance or discordance of the results, information on the quantity of pneumococci present in the sample of respiratory tract secretions can be obtained.
[0099] Indeed, and as presented in the experimental section, a correlation between the quantitative results of the bacterial culture and the results of the immuno-munological test used in the process of the invention could be established in parallel, and therefore it is possible to state that: - if both detection steps (i) and (ii) resulted in a positive result, this is representative of a pneumococci count in the sample greater than or equal to 107 CFU / ml; and - if step (i) resulted in a positive result and step (ii) resulted in a negative result, this is representative of a quantity of pneumococci in the sample of between approximately 103 and approximately 106 CFU / ml.
[0100] Thus, as shown in Figure 1, in the case where both detection steps (i) and (ii) have resulted in a "positive" result, then the patient is likely suffering from an invasive pneumococcal infection.
[0101] Conversely, if the detection step (i) resulted in a "positive" result and the detection step (ii) resulted in a "negative" result, then the patient is likely an asymptomatic carrier of pneumococci.
[0102] Naturally, other complementary diagnostic methods may be carried out to confirm these presumptions.
[0103] Advantageously, the diagnostic method according to the invention makes it possible to distinguish between the following two cases: - patients with invasive pneumococcal infection, and - patients who are asymptomatic carriers of S. pneumoniae, or who are recovering from a recent but completed infection.
[0104] According to one embodiment of the invention, the in vitro diagnostic method comprises the following steps: i) detection of the presence of at least one pneumococcal antigen, on a sample of secretions from the respiratory tract of a patient, by the implementation of an immunological test; ii) dilution of said sample, then detection of the presence of at least one pneumococcal antigen by implementing the same immunological test as in (i) on said diluted sample; iii) comparison of the results obtained in steps (i) and (ii).
[0105] This process is presented schematically in Figure 1.
[0106] According to a particular implementation, the diagnostic process consists of the three steps (i), (ii) and (iii).
[0107] According to another embodiment, the diagnostic process includes other complementary steps, including: - a step of bacterial culture on agar of the sample tested, for confirm the absence of an invasive pneumococcal infection; and / or - an amplification step of a gene from S. pneumoniae in the sample tested; These additional steps are particularly recommended in the case of different results between the first and second detection steps.
[0108] According to one embodiment of the process, it further comprises a step (iv) of bacteriological culture from the sample of secretions from the patient's respiratory tract.
[0109] This application also relates to a method for treating an invasive pneumococcal infection, comprising the following steps: (i) detection of the presence of at least one pneumococcal antigen, on a sample of secretions from the respiratory tract of an individual likely to be affected by an invasive pneumococcal infection, by the implementation of an immunological test; ii) dilution of said sample, then detection of the presence of at least one pneumococcal antigen by implementing the same immunological test as in (i) on said diluted sample; iii) comparison of the results obtained in steps (i) and (ii), (iv) in the event that both detection steps (i) and (ii) result in a positive result, administration of an antibiotic suitable for the said individual.
[0110] The appropriate antibiotic will be either an antibiotic with specific action against S. pneumoniae, or a broad-spectrum antibiotic with action against S. pneumoniae. Diagnostic kit
[0111] The present invention also relates to a diagnostic kit for carrying out the in vitro process as described above, comprising: - an immunological test comprising at least one antibody that binds specifically to at least one pneumococcal antigen; and - a suitable dilution solution for diluting a sample of secretions from an individual's respiratory tract.
[0112] Advantageously, this kit will include reagents suitable for the pneumococcal antigen detection step.
[0113] Advantageously, said kit will also include instructions for use.
[0114] Advantageously, the said kit may be stored at room temperature.
[0115] According to another embodiment, this kit will further include a fluidizing agent intended to be added to the secretion sample.
[0116] A kit including a fluidizing agent will preferably be kept at a temperature below 5°C, for the purposes of preserving the fluidizing agent in liquid form.
[0117] However, if the fluidizing agent is incorporated into the kit in powder form, the kit will then include a suitable solvent for dissolving the fluidizing agent, and the kit can be stored at room temperature. Examples
[0118] Example 1. Tested population and conventional diagnostic tests 1.1. Patient population
[0119] Two hundred and two (202) samples from the respiratory tract (nasopharyngeal secretions and sputum) were collected from children admitted to the University Hospital of Saint-Étienne (France). The subjects included were under 15 years of age and were admitted to the pediatric emergency department, pediatrics, or intensive care unit. The collection and analysis of clinical, radiological, and biological data were performed retrospectively.
[0120] The diagnosis of S. pneumoniae pneumonia was defined on the coexistence of: (i) suggestive clinical criteria, (ii) an abnormal parenchymal image on chest X-ray, and (iii) of a culture greater than or equal to 107 CFU of S. pneumoniae in semi-quantitative bacteriology. (Harris et al., 2011).
[0121] The demographic and clinical characteristics of the patient cohort are listed in Table 1 below.
[0122] [Tables 1] Characteristics Numerical data Demographic characteristics Number of subjects 202 Mean age (years) 2.5 (0-15) Median age (years) 0.83 Interquartile range (years) 0.17-2.72 Sex ratio (boys / girls) 1.20 Reason for consultation Dyspnea 93 (46.0%) Cough 32 (15.8%) Hyperthermia 44 (21.8%) Other (Mainly: abdominal pain and diarrhea) 33 (16.3%) Antibiotic therapy prior to emergency department visit 18 (8.9%) Chest X-ray 129 (63.9%) Pulmonary focus 38 (18.8%) Interstitial syndrome 61 (30.2%) Departments 160 (79.2%) Pediatric emergency department 189 (93.5%) Intensive care unit 11 (5.5%) Pediatrics 2 (1.0%) Mean length of hospital stay (days) 5.1 Return home after emergency room visit 42 (44.9%) Biological inflammatory syndrome 63 (31.2%) Pneumonia 123 (60.9%) S. pneumoniae pneumonia 29 (14.3%)
[0123] Demographic and clinical characteristics of the patient cohort
[0124] 1.2. Bacteriological identification of S. pneumoniae by culture
[0125] The samples taken were liquefied with an equivalent volume of a solution sterile dithiothreitol (Digest-EUR®, Eurobio, France) for the production of semi-quantitative cultures.
[0126] The undiluted pretreated sample and 102 dilutions were inoculated onto four agar plates: blood agar (COS, BioMérieux) with an optochin disc (OPTO-F, BioMérieux), Columbia ANC agar based on dehydrated medium (BBL™ Columbia agar, BD) and defibrinated sheep blood (Thermofisher), purple lactose bromocresol agar (BCP agar, BioMérieux), and chocolate agar (PVX agar, BioMérieux). The plates were incubated in an incubator at 37°C under 5% CO2 (Arbique et al., 2004).
[0127] A reading was taken at 24h and 48h and the colony count was expressed in CFU / ml.
[0128] Colony identification was made presumptively on phenotypic characteristics: flat, alpha-hemolytic colonies sensitive to optochin (diameter >15mm), then confirmed using a Microflex LT mass spectrometer (Bruker Daltonics, Bremen, Germany).
[0129] In addition, a bile salt lysis test in a test tube was performed on each isolated strain, following the manufacturer's recommendations (BBL™ Desoxycholate Reagent Droppers, BD). A positive result with this test allows the Streptococcus pneumoniae species to be distinguished from other non-pneumoniae streptococci of the mitis group.
[0130] 1.3. Amplification of S. pneumoniae genes by PCR
[0131] Two PCR (Polymerase Chain Reaction) techniques were used to detect S. pneumoniae directly in patient samples, one targeting the ply (pneumolysin) gene and the other the lytA (autolysin) gene, which correspond to the two main virulence factors of the bacterium.
[0132] In brief, 200 µl of sample were pretreated with 20 µl of proteinase K (Eurobio, France) for 10 minutes at 50°C and then extracted using the EasyMag analyzer (BioMérieux, France) following the manufacturer's recommendations. The samples were eluted in 110 µl of elution buffer and stored frozen at -20°C before testing. The primers and probes used (Eurogentec, France) are shown in Table 2 (Carvalho et al., 2QQH).
[0133] [Tables 2] Designation Type Sequences 5' - 3' Size (bp) Reference Gene ply - SPply F Sense TGCAGAGCGTCCTTTGGTCTAT 22 SEQID NO:1 - SPply R Anti-sense CTCTTACTCGTGGTTTCCAACTT GA 25 SEQ ID NO:2 - SPply TP Probe TTCGAGTGTTGCTTATGGGCGCC A 24 SEQ ID NO:3 Gene lytA - LytA F Sens CGCAATCTAGCAGATGAAGCAG 22 SEQ ID NO: 4 - LytA R Anti-sense AAGGGTCAACGTGGTCTGAGTG 21 SEQ ID NO: 5 - LytA Pr Probe TTTGCCGAAAACGCTTGATACAG GG 25 SEQ ID NO: 6
[0134] Primer and probe sequences used for the detection and identification of S. pneumoniae
[0135] 1.4. The microbiological results of the 202 samples in the study are presented in Table 3 below.
[0136] [Tables3] Technical Data Numerical Culture Positive for S. pneumoniae > 10⁵ CFU / ml > 10⁶ CFU / ml 7371 > 10⁷ CFU / ml 56 Positive PCR Tests (ply and / or lytA) 180 (89.1%) Ply 178 (88.1%) lytA 132 (65.3%)
[0137] Microbiological results of the 202 samples from example 1
[0138] Semi-quantitative cultures for S. pneumoniae
[0139] Of the 202 samples, 73 strains of S. pneumoniae were isolated. Semi-quantitative data are shown in Table 3. These strains were all susceptible to The optochin and bile salt lysis tests were also all positive.
[0140] Quantitative PCR tests and correlation with culture
[0141] Of 202 samples, 178 were positive for the ply gene and 132 were positive for the lytA gene. The sensitivity of the two techniques was evaluated by determining the limit of quantification: 102 CFU / ml for ply and 103 CFU / ml for lytA.
[0142] The correlation between the cycle positivity (Ct) of each of the two PCR reactions, which is proportional to the bacterial load of the sample, and the semi-quantification of a S. pneumoniae suspension culture, was performed using a colony counter (Scan 1200, Interscience). The respective Ct values of each PCR were correlated with the S. pneumoniae CFU / ml quantification, and the equivalence results of these two semi-quantitative techniques are shown in Figure 2.
[0143] Next, a correlation was made between the Ct of the PCR test detecting the ply gene expressed in CFU / ml taking into account the values in Figure 2, and the results of the semi-quantitative culture (Table 4).
[0144] [Tables4] Culture quantification PCR quantification ply > 107 CFU / ml 106CFU / ml 105 CFU / ml <102 CFU / ml* > 107 CFU / ml 42 14 0 0 106 CFU / ml 8 7 0 0 105 CFU / ml 0 2 0 0 <104 CFU / ml** 15 41 49 24
[0145] Equivalence between semi-quantification by culture and by RT-PCR.
[0146] *PCR ply detection threshold
[0147] **Threshold of quantification of bacterial culture
[0148] Among the 105 samples positive by PCR and negative by culture, 49 (46.7%) had a bacterial load (evaluated by PCR) <105 CFU / ml and 15 (14.3%) corresponded to patients under antibiotic treatment, which explains this discrepancy.
[0149] Example 2. Diagnostic method for S. pneumoniae infection using a "PneumoResp" immunochromatographic test. 2.1. Steps of the implemented method
[0150] PneumoResp is an immunochromatographic test detecting capsular polysaccharides (CWPS) of S. pneumoniae.
[0151] PneumoResp employs a pair of antibodies directed against capsular polysaccharides. Gold nanoparticles coupled to the specific antibodies will interact with capsular antigens if present in the sample; by migrating with the sample along a nitrocellulose membrane, the complexes composed of capsular antigens and the gold-conjugated antibody bind to the test line (immunocapture line), resulting in the appearance of a reddish band at the test line T (if the test is positive) and the control line C (whether the test is positive or negative). The absence of the control band indicates an uninterpretable test.
[0152] This test is designated “TDR” in the figures, for Rapid Diagnostic Test.
[0153] Step 1 - The sputum sample is liquefied by adding (1 volume of sample to 1 volume of diluent) a reagent such as Digest-EUR® (Eurobio) or Sputasol (ThermoFisher).
[0154] Step 2 - Collect approximately 1 millilitre of liquefied sputum and place it in tube 1; vortex for 10 seconds.
[0155] Step 3 - Place one drop of the treated sample from tube 1 into the "sample" well S, followed by three drops of the PneumoResp test buffer (diluent buffer). Start the timer. A reddish colored front will move from bottom to top along the membrane. The reading can be made visually (it can also be performed with a suitable reader). The results are only valid after the control line appears. The final test reading is taken at 15 minutes, but positive results may appear before then.
[0156] Step 4 - If this first test is positive, the treated sample from tube 1 is then processed in tube 2. To do this, take 10 microliters of the remaining treated sample from tube 1 and mix it with the contents of tube 2 (dilution by one-hundredth). Vortex the mixture for 10 seconds.
[0157] Step 5 - Step 3 is repeated.
[0158] The results of steps 3 and 5 are said to be "positive" if a red band appears in line T and in line C. They are said to be "negative" if no band appears in line T but nevertheless a line appears in line C, as shown in Figure 4.
[0159] The first detection step is called "PURE", i.e., carried out on an undiluted sample; the second detection step is called "DILUTE", i.e., carried out on a sample diluted by a factor of 100.
[0160] The specificity of the test was evaluated on 35 bacterial species, including 13 belonging to the genus Streptococcus of the mitis group (Streptococcus mitis, Streptococcus oralis and Streptococcus pseudopneumoniae) in order to verify the absence of cross-reactions with the antigens used with regard to the bacteria potentially present in the respiratory flora.
[0161] Furthermore, no cross-reactivity was observed for the other species listed below: Alloscardovia omnicolens, Enterococcus avium, Enterococcus faecalis, Ente- rococcus faecium, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Staphylococcus aureus, Streptococcus agalactiae, Streptococcus anginosus, Streptococcus constellatus, Streptococcus gordonii, Streptococcus pyogenes, Streptococcus salivarius, Streptococcus sanguineis, Streptococcus para-sanguinis, Streptococcus mitis and Streptococcus vestibularis.
[0162] 2.2. Results obtained with the "PneumoResp" test:
[0163] The test was evaluated on 202 samples from the respiratory tract (nasopharyngeal secretions and sputum) from children admitted to the University Hospital of Saint-Etienne (France). The subjects included were under 15 years of age and were admitted to the pediatric emergency department, pediatrics, or intensive care unit.
[0164] Of the 202 samples, 65 were negative and 137 were positive in the first stage of detection.
[0165] The samples that found positive were retested after dilution. At the end of this second detection step, 79 samples were positive and 58 were negative.
[0166] Example 3. Comparison of the results obtained in Example 1 with conventional diagnostic protocols (bacterial culture, PCR) and the results obtained by implementing the method according to the invention, in Example 2. 3.1. Statistical analysis
[0167] Descriptive variables, sensitivity (Se), specificity (Sp), and positive predictive values (PPV) and negative predictive values (NPV) are reported with their 95% confidence intervals (CI). Parametric and nonparametric tests and graphs were performed using GraphPad Prism 5 software (California, USA). P-values less than 5% were considered statistically significant.
[0168] 3.2. Performance comparison: raw results
[0169] The performance of the diagnostic method according to the invention, compared with that of conventional techniques (bacteriological culture, and gene amplification by PCR) is presented in Table 5 below.
[0170] [Tables 5] RDT Result Positive Culture for S. pneumoniae Positive Negative Sensitivity% (95% CI) Specificity% (95% CI) PPV% (95% CI) NPV% (95% CI) Total (n=202) Pure RDT 100 (95.1-100) 50.4 (41.5-59.3) 53.3 (48.9-57.8) 100 (95.1-100) Positive 73 64 Negative 0 65 Diluted RDT 91.8 (83.0-97.0) 81.3 (70.0-90.0) 84.8 (77.0-90.3) 89.7 (80.0-95.0) Positive 67 12 Negative 6 52 Culture >107 CFU / ml of S. pneumoniae Positive Negative Sensitivity% (95% CI) Specificity% (95% CI) PPV% (95% CI) NPV% (95% CI) Total (n=202) Pure RDT 100 (93.6-100) 44.5 (36.6-53.0) 40.9 (37.4-44.4) 100 (93.6-100) Positive 56 81 Negative 0 65 Diluted RDT 94.6 (85.1-98.9) 67.9 (56.6-77.8) 67.1 (59.6-73.8) 94.8 (85.7-98.2) Positive 53 26 Negative 3 55 Quantitative PCR >10⁷ CFU / ml (ply gene) Positive Negative Sensitivity% (95% CI) Specificity% (95% CI) 95%) PPV% (95% CI) NPV% (95% CI) Total (n=202) Pure RDT 98.6 (92.2-100) 48.1 (39.4-57.0) 49.6 (45.5-53.8) 98.5 (90.1-99.8) Positive 68 69 Negative 1 64 Diluted RDT 90.6 (80.7-96.5) 71.2 (59.4-81.8) 73.4 (65.2-80.0) 89.7 (80.0-95.0) Positive 58 21 Negative 6 52 Quantitative PCR >10⁷ CFU / ml (lytA gene) Positive Negative Sensitivity% (95% CI) Specificity% (95% CI) PPV% (95% CI) NPV% (95% CI) Total (n=202) Pure RDT 100 (87.2-100) 37.1 (30.0-44.8) 19.7 (18.0-21.6) 100 (87.2-100) Positive 27 110 Negative 0 65 Diluted RDT 96.3 (81.0-100) 51.8 (42.1-61.4) 32.9 (28.5-37.6) 98.3 (89.2-99.8) Positive 26 53 Negative 1 57 S. pneumoniae Pneumonia Positive Negative Sensitivity% (95% CI) Specificity% (95% CI) PPV% (95% CI) NPV% (95% CI) Total (n=202) Pure RDT 100 (88.1-100) 37.6 (30.3-45.2) 21.2 (19.3-23.1) 100 (88.1-100) Positive 29 108 Negative 0 65 Diluted RDT 100 (88.1-100) 53.7 ((43.8-63.4) 36.7 (32.1-41.5) 100 (88.1-100) Positive 29 50 Negative 0 58
[0171] Comparison of the performance of the diagnostic method according to the invention with the results of conventional techniques (bacteriological culture and gene amplification by PCR)
[0172] 3.3. Performance of the process according to the invention with respect to the results of bacterial culture:
[0173] The performance of this test compared to the culture of S. pneumoniae was as follows: - sensitivity (Se) of 100% [95% CI: 95.1-100], - specificity (Sp) of 50.4% [95% CI: 41.5-49.3], - positive predictive value (PPV) of 53.3% [95% CI: 48.9-57.8] and - negative predictive value (NPV) of 100% [95% CI: 95.1-100].
[0174] Se and NPV remain at 100% compared to culture >107 CFU / ml (100% [95% CI: 93.6-100]) of S. pneumoniae and compared to lytA PCR with a quantification threshold >107 CFU / ml (100% [95% CI: 87.2-100]).
[0175] The sensitivity compared to PCRply is 98.6% [95% CI: 92.2-100]. Indeed, only one sample was found to be negative during the first detection step, and had a Ct close to the threshold (Ct of 21.96 for 22 cycles) for PCRply (see Figure 3).
[0176] Moreover, out of the 202 samples, only 4 were positive during the first detection stage, and at the same time negative in PCR ply.
[0177] Among the 65 negative tests in the first stage of detection, no child had S. pneumoniae pneumonia. The NPV and Se were 100%.
[0178] 3.4. A method comprising two detection steps, on a pure sample and then on diluted sample:
[0179] The samples that tested positive were retested after dilution. At the end of this second step, 79 samples were found to be positive and 58 were found to be negative.
[0180] The performance of this process compared to culture was as follows: - Se of 91.8% [95% CI: 83.0-97.0],
[0181] - Sp of 81.3% [95% CI: 70.0-90.0],
[0182] - PPV of 84.8% [95% CI: 77.0-90.3] and
[0183] - NPV of 89.7% [95% CI: 80.0-95.0],
[0184] Taking into account the quantified culture >107 CFU / ml of S. pneumoniae, the performance is as follows:
[0185] - Se of 94.6% [95% CI: 85.1-98.9],
[0186] - Sp of 67.9 [95% CI: 56.6-77.8],
[0187] - PPV of 67.1% [95% CI: 59.6-73.8] and
[0188] - NPV of 94.8% [95% CI: 85.7-98.2],
[0189] In addition, all cases of S. pneumoniae pneumonia (n=29) were found to be positive in the second detection step. The performance of the test after the dilution step compared to the clinical diagnosis of S. pneumoniae pneumonia was as follows:
[0190] - Se of 100% [95% CI: 88.1-100],
[0191] - Sp of 53.7% [95% CI: 43.8-63.4],
[0192] - PPV of 36.7% [95% CI: 32.1-41.5] and
[0193] - VPN 100% [95% CI: 8.1-100],
[0194] 3.5. Summary analysis of the study results
[0195] In this study, the results obtained were compared to semi-quantitative culture on fresh blood agar and cooked blood agar at 48 hours, considered the "gold standard" for the diagnosis of S. pneumoniae pneumonia. (Table 6)
[0196] For all patients who tested negative in the first stage of detection (n = 65), clinical and radiological analysis combined with a negative pneumococcal culture ruled out the diagnosis of pneumococcal pneumonia. These results indicate a sensitivity of 100% (73 / 73) and a negative predictive value of 100% (65 / 65).
[0197] [Tableauxô] Semi-quantitative PneumoResp culture on pure liquefied sputum Positive Negative Total Positive 73 64 137 Negative 0 65 65 Total 73 129 202
[0198] Comparison of the results of semi-quantitative culture and PneumoResp on undiluted liquefied sputum from 202 pediatric sputum samples.
[0199] This excellent negative predictive value of the procedure performed on undiluted fluidized sputum makes it possible to exclude pneumococcal pneumonia with near certainty in the event of a negative result of the detection test.
[0200] The 137 samples found positive on thinned sputum were retested after dilution of the respiratory secretion samples (detection step 2). The results were compared to the final diagnosis of pneumococcal pneumonia based on clinical and radiological data, laboratory tests, testing for other respiratory pathogens, and a positive pneumococcal culture at the threshold of at least 10⁷ CFU per ml (REMIC).
[0201] All patients labeled in this study as having pneumococcal pneumonia (n = 29) were found to be positive at both detection stages (without dilution and after dilution to one hundredth) by the method of the invention.
[0202] The excellent sensitivity (29 / 29, 100%) of the method of the invention with 2 detection steps on the liquefied sputum makes it possible to suspect from the first day, with a very high probability, an invasive pneumococcal infection and therefore to offer appropriate antibiotic treatment early.
[0203] Example 4. Characteristics of the immunochromatographic test "PneumoResp"
[0204] Materials and reagents supplied: - twenty (20) individual "test" cassettes contained in airtight pouches with desiccant - twenty (20) single-use plastic dropper pipettes - a vial of preparatory treatment "Tube 1" and for making the fluidized sample compatible with the PneumoResp reagents - a sample preparation vial "Tube 2" for the second test in case the first test is positive - a bottle of pusher thinner - a positive control vial - an instruction manual.
[0205] Required but not supplied equipment and reagents: - a micropipette with disposable tips allowing for the collection of 10 microliters - a vortex - a micropipette with disposable tips allowing for the collection of 1 milliliter - stopwatch or timer - Standard sterile containers for collecting sputum, bronchial secretions or expectoration - container for biological waste - disposable gloves.
[0206] Important: To interpret the test, it is essential to observe the presence of the control line; it ensures that the volume of sample tested is sufficient and that the described procedure is carried out correctly. This control line must appear within 15 minutes (before or after the test line if the latter is positive).
[0207] Positive test: Presence of two distinct bands: a control line appears at the level of zone C and a reddish line, even of low intensity, appears at the level of zone T.
[0208] Negative test: Only a reddish line appears in the control area C. No line appears in the T area.
[0209] Invalid test: No visible reddish line appears in control area C regardless of the result in area T.
[0210] An internal control system is integrated into each cassette. Specifically, the change in color from pink to purple on the control line (C) is considered an internal control. A colored line appears on the control line to indicate that the user has added a sufficient sample volume and that the test is being conducted correctly. Heavy coloration of the reading area on the cassette can lead to an inaccurate control reading. It should be a very light pink to white within 15 minutes and should not interfere with the reading of the results. List of cited documents
[0211] Izumikawa, K., Akamatsu, S., Kageyama, A., Okada, K., Kazuyama, Y., Takayanagi, N., & Ishida, T. (2009). Evaluation of a rapid immunochromatographic ODK0501 assay for detecting Streptococcus pneumoniae antigen in sputum samples from patients with lower respiratory tract infection. Clin. Vaccine Immunol., 16(5), 672-678.
[0212] Ehara, N., Fukushima, K., Kakeya, H., Mukae, H., Akamatsu, S., Kageyama, A.,& Kohno, S. (2008). A novel methodfor rapid détection of Streptococcus pneumoniae antigen in sputum and its application in adult respiratory tract infections. Journal of medical microbiology, 57(7), 820-826.
[0213] Ikegame, S., Nakano, T., Otsuka, J., Yoshimi, M., Matsuo, T., Kubota, M., & Takata, S. (2017). The Evaluation ofthe Sputum Antigen Kit in the Diagnosis of Pneumococcal Pneumonia. Internai Medicine, 56(10), 1141-1146.
[0214] Harris, M., Clark, J., Coote, N., Fletcher, P., Harnden, A., McKean, M., & Thomson, A. (2011). British Thoracic Society guidelines for the management of community acquiredpneumonia in children: update 2011. Thorax, 66(Suppl 2), Ü1-Ü23.
[0215] Arbique JC, Poyart C, Trieu-Cuot P, Quesne G, Carvalho MGS, Steigerwalt AG, Morey RE, Jackson D, Davidson RJ, Facklam RR. Accuracy of phenotypic and genotypic testing for identification of Streptococcus pneumoniae and description of Streptococcus pseudopneumoniae sp. nov. J Clin Microbiol 2004;42:4686-96.
[0216] Carvalho Mda G, Tondella ML, McCaustland K, Weidlich L, McGee L, Mayer LW, Steigerwalt A, Whaley M, Facklam RR, Fields B, Carlone G, Ades EW, Dagan R, Sampson JS. Evaluation and improvement of real-time PCR assays targeting lytA, ply, and psaA genesfor détection of pneumococcal DNA. J Clin Microbiol. 2007;45:2460-6.
Claims
Claims
1. Method for in vitro diagnosis of a pneumococcal infection (Strep-tococcus pneumoniae) comprising at least two steps of detecting a pneumococcal antigen: (i) on a sample of secretions from the respiratory tract of a patient, and (ii) on the same sample after dilution.
2. Diagnostic method according to claim 1, characterized in that in step (ii) the sample is diluted by a dilution factor of 10 to 1000, preferably by a factor of 100.
3. Diagnostic method according to claim 1 or 2, characterized in that each detection step is carried out using an immunological test comprising at least one antibody binding specifically to at least one pneumococcal antigen.
4. Diagnostic method according to one of claims 1 to 3, characterized in that the sample has been previously fluidized.
5. Diagnostic method according to one of claims 1 to 4, characterized in that at the end of each detection step, a “positive” or “negative” result is obtained.
6. Diagnostic method according to one of claims 1 to 5, characterized in that obtaining a “negative” result in detection step (i) is representative of a quantity of pneumococci in the sample less than or equal to 103 CFU / ml.
7. Diagnostic method according to one of claims 1 to 6, further comprising a step (iii) of comparing the results obtained in steps (i) and (ii).
8. Diagnostic method according to claim 7, characterized in that: - if the two detection steps (i) and (ii) have resulted in a positive result, this is representative of a quantity of pneumococci in the sample greater than or equal to 107 CFU / ml; and - if step (i) has resulted in a positive result and step (ii) has resulted in a negative result, this is representative of a quantity of pneumococci in the sample of between approximately 103 and approximately 106 CFU / ml.
9. Diagnostic method according to one of claims 1 to 8, characterized in that the patient is less than 12 years old.
10. Diagnostic method according to one of claims 1 to 9, comprising in addition a step (iv) of bacteriological culture from the sample of secretions from the patient's respiratory tract.
11. Diagnostic kit for implementing the in vitro method according to one of claims 1 to 10, comprising: - an immunological test comprising at least one antibody specifically binding to at least one pneumococcal antigen; and - a dilution solution.
